These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 35835205)

  • 1. Elevated de novo lipogenesis, slow liver triglyceride turnover, and clinical correlations in nonalcoholic steatohepatitis patients.
    Lawitz EJ; Li KW; Nyangau E; Field TJ; Chuang JC; Billin A; Wang L; Wang Y; Huss RS; Chung C; Subramanian GM; Myers RP; Hellerstein MK
    J Lipid Res; 2022 Sep; 63(9):100250. PubMed ID: 35835205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acetyl-CoA Carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic Steatohepatitis.
    Lawitz EJ; Coste A; Poordad F; Alkhouri N; Loo N; McColgan BJ; Tarrant JM; Nguyen T; Han L; Chung C; Ray AS; McHutchison JG; Subramanian GM; Myers RP; Middleton MS; Sirlin C; Loomba R; Nyangau E; Fitch M; Li K; Hellerstein M
    Clin Gastroenterol Hepatol; 2018 Dec; 16(12):1983-1991.e3. PubMed ID: 29705265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Palmitoleic acid is elevated in fatty liver disease and reflects hepatic lipogenesis.
    Lee JJ; Lambert JE; Hovhannisyan Y; Ramos-Roman MA; Trombold JR; Wagner DA; Parks EJ
    Am J Clin Nutr; 2015 Jan; 101(1):34-43. PubMed ID: 25527748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation.
    Bates J; Vijayakumar A; Ghoshal S; Marchand B; Yi S; Kornyeyev D; Zagorska A; Hollenback D; Walker K; Liu K; Pendem S; Newstrom D; Brockett R; Mikaelian I; Kusam S; Ramirez R; Lopez D; Li L; Fuchs BC; Breckenridge DG
    J Hepatol; 2020 Oct; 73(4):896-905. PubMed ID: 32376414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fasting hepatic de novo lipogenesis is not reliably assessed using circulating fatty acid markers.
    Rosqvist F; McNeil CA; Pramfalk C; Parry SA; Low WS; Cornfield T; Fielding BA; Hodson L
    Am J Clin Nutr; 2019 Feb; 109(2):260-268. PubMed ID: 30721918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acetyl-CoA Carboxylase Inhibition Improves Multiple Dimensions of NASH Pathogenesis in Model Systems.
    Ross TT; Crowley C; Kelly KL; Rinaldi A; Beebe DA; Lech MP; Martinez RV; Carvajal-Gonzalez S; Boucher M; Hirenallur-Shanthappa D; Morin J; Opsahl AC; Vargas SR; Bence KK; Pfefferkorn JA; Esler WP
    Cell Mol Gastroenterol Hepatol; 2020; 10(4):829-851. PubMed ID: 32526482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acetyl-coenzyme A carboxylase inhibition reduces de novo lipogenesis in overweight male subjects: A randomized, double-blind, crossover study.
    Stiede K; Miao W; Blanchette HS; Beysen C; Harriman G; Harwood HJ; Kelley H; Kapeller R; Schmalbach T; Westlin WF
    Hepatology; 2017 Aug; 66(2):324-334. PubMed ID: 28470676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH).
    Alkhouri N; Lawitz E; Noureddin M; DeFronzo R; Shulman GI
    Expert Opin Investig Drugs; 2020 Feb; 29(2):135-141. PubMed ID: 31519114
    [No Abstract]   [Full Text] [Related]  

  • 9. Acetyl-CoA carboxylase inhibitors in non-alcoholic steatohepatitis: Is there a benefit?
    Neokosmidis G; Cholongitas E; Tziomalos K
    World J Gastroenterol; 2021 Oct; 27(39):6522-6526. PubMed ID: 34754150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective Acetyl-CoA Carboxylase 1 Inhibitor Improves Hepatic Steatosis and Hepatic Fibrosis in a Preclinical Nonalcoholic Steatohepatitis Model.
    Tamura YO; Sugama J; Iwasaki S; Sasaki M; Yasuno H; Aoyama K; Watanabe M; Erion DM; Yashiro H
    J Pharmacol Exp Ther; 2021 Nov; 379(3):280-289. PubMed ID: 34535562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease.
    Smith GI; Shankaran M; Yoshino M; Schweitzer GG; Chondronikola M; Beals JW; Okunade AL; Patterson BW; Nyangau E; Field T; Sirlin CB; Talukdar S; Hellerstein MK; Klein S
    J Clin Invest; 2020 Mar; 130(3):1453-1460. PubMed ID: 31805015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigating dual inhibition of ACC and CD36 for the treatment of nonalcoholic fatty liver disease in mice.
    Devereux CJ; Bayliss J; Keenan SN; Montgomery MK; Watt MJ
    Am J Physiol Endocrinol Metab; 2023 Feb; 324(2):E187-E198. PubMed ID: 36629823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Dietary Fructose and Hepatic De Novo Lipogenesis in Fatty Liver Disease.
    Softic S; Cohen DE; Kahn CR
    Dig Dis Sci; 2016 May; 61(5):1282-93. PubMed ID: 26856717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acetyl-CoA carboxylase 1 and 2 inhibition ameliorates steatosis and hepatic fibrosis in a MC4R knockout murine model of nonalcoholic steatohepatitis.
    Matsumoto M; Yashiro H; Ogino H; Aoyama K; Nambu T; Nakamura S; Nishida M; Wang X; Erion DM; Kaneko M
    PLoS One; 2020; 15(1):e0228212. PubMed ID: 31990961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dietary sugar restriction reduces hepatic de novo lipogenesis in adolescent boys with fatty liver disease.
    Cohen CC; Li KW; Alazraki AL; Beysen C; Carrier CA; Cleeton RL; Dandan M; Figueroa J; Knight-Scott J; Knott CJ; Newton KP; Nyangau EM; Sirlin CB; Ugalde-Nicalo PA; Welsh JA; Hellerstein MK; Schwimmer JB; Vos MB
    J Clin Invest; 2021 Dec; 131(24):. PubMed ID: 34907907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fructose as a key player in the development of fatty liver disease.
    Basaranoglu M; Basaranoglu G; Sabuncu T; Sentürk H
    World J Gastroenterol; 2013 Feb; 19(8):1166-72. PubMed ID: 23482247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acetyl-CoA carboxylase inhibitor increases LDL-apoB production rate in NASH with cirrhosis: prevention by fenofibrate.
    Dandan M; Han J; Mann S; Kim R; Li K; Mohammed H; Chuang JC; Zhu K; Billin AN; Huss RS; Chung C; Myers RP; Hellerstein M
    J Lipid Res; 2023 Mar; 64(3):100339. PubMed ID: 36737040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose-dependent quantitative effects of acute fructose administration on hepatic de novo lipogenesis in healthy humans.
    Beysen C; Ruddy M; Stoch A; Mixson L; Rosko K; Riiff T; Turner SM; Hellerstein MK; Murphy EJ
    Am J Physiol Endocrinol Metab; 2018 Jul; 315(1):E126-E132. PubMed ID: 29558206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acetyl-CoA Carboxylase Inhibition Reverses NAFLD and Hepatic Insulin Resistance but Promotes Hypertriglyceridemia in Rodents.
    Goedeke L; Bates J; Vatner DF; Perry RJ; Wang T; Ramirez R; Li L; Ellis MW; Zhang D; Wong KE; Beysen C; Cline GW; Ray AS; Shulman GI
    Hepatology; 2018 Dec; 68(6):2197-2211. PubMed ID: 29790582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sex-Specific Differences in Hepatic Fat Oxidation and Synthesis May Explain the Higher Propensity for NAFLD in Men.
    Pramfalk C; Pavlides M; Banerjee R; McNeil CA; Neubauer S; Karpe F; Hodson L
    J Clin Endocrinol Metab; 2015 Dec; 100(12):4425-33. PubMed ID: 26414963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.